Tofacitinib in Rheumatology: From evidences to clinical practices

Speciality: Rheumatology


Speaker:

Dr. Bharat Kumar Singh - Moderator | Rheumatologist

Dr. Bhupendra Vaishnav - Panelist | Rheumatologist

Dr. Avinash Jain - Panelist | Rheumatologist

Dr. Mohit Goyal - Panelist | Rheumatologist

Dr. Aadhaar Dhooria - Panelist | Rheumatologist

Description:

A warm welcome to all the medical professionals in this interesting session on Tofacitinib in Rheumatology: From evidences to clinical practices.

Tofacitinib has emerged as a promising treatment in rheumatology, especially for conditions like rheumatoid arthritis. It offers a new option for patients who have not found relief with traditional therapies, making a significant impact on their quality of life. This medication works by targeting specific enzymes involved in the immune response, helping to reduce inflammation and pain in a more precise way.

One of the key benefits of tofacitinib is its oral administration, which is more convenient than injectable alternatives. This makes it easier for patients to adhere to their treatment plan, improving outcomes in the long run. Clinical studies have shown that tofacitinib not only reduces symptoms but also slows the progression of joint damage, offering long-term benefits for those with chronic inflammatory diseases.

However, like all medications, tofacitinib comes with potential risks. Patients need regular monitoring to ensure that side effects, such as an increased risk of infections, are managed properly. Despite these concerns, tofacitinib represents a major advancement in the field, transforming research into practical relief for those living with rheumatic diseases.

Therefore, get an overall knowledge of tofacitinib in rheumatology: from evidences to clinical practices. Listen to the webinar, grab the shared knowledge, and follow Hidoc for more such interesting webinar sessions.
 See More Webinars @ Hidoc Webinars




Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

A hint regarding aspirin, the connection to colon cancer, the approval of the new Lutathera, artificial intelligence, and electronic records.

2.

Study: One-week breast cancer radiotherapy proven as safe and effective as standard three-week treatment

3.

Racial differences seen in epigenetic age acceleration in childhood cancer survivors

4.

ASTRO Guideline Addresses Specifics of HPV-Associated Oropharyngeal Cancer

5.

Taking the "Boob Bus"; Reluctance to Grant Prior Authorization; Alcohol's Carcinogenic Potential?


© Copyright 2026 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
bot